newsfilter
← Latest News
GlobeNewswire·

Moleculin Secures Australian Patent for Annamycin Formulation Technology

MBRX
  • Moleculin Biotech, Inc. announced the grant of Australian Patent No. 2020303572 covering the preparation of preliposomal Annamycin lyophilizate.
  • The patent was issued jointly to Moleculin Biotech & The Board of Regents of The University of Texas System.
  • This grant strengthens Moleculin's international intellectual property portfolio for Annamycin's formulation technology.
  • Moleculin holds granted or allowed patents in the United States, Canada, China, Europe, India, Israel, Japan, Mexico, Singapore, & Taiwan.
  • The patent application is pending formal grant in South Africa, while applications remain pending in other jurisdictions including South Korea.
  • Annamycin is an investigational anthracycline being evaluated for relapsed or refractory acute myeloid leukemia (AML) & soft tissue sarcoma lung metastases.
  • The drug is designed to avoid multidrug resistance mechanisms & lack the cardiotoxicity common with conventional anthracyclines.
  • Moleculin is conducting the MIRACLE trial (MB-108), a pivotal Phase 2/3 study evaluating Annamycin combined with cytarabine (AnnAraC) for AML.
  • Following a successful Phase 1B/2 study, Moleculin believes it has substantially de-risked the development pathway toward potential AML approval.
  • The Company also develops WP1066 for brain & pancreatic cancers, & WP1122 for pathogenic viruses.
  • Moleculin requires significant additional financing to conduct its clinical trials, with no current commitments secured.
Company
Moleculin Biotech, Inc.
Keywords
Nasdaq:MBRX, Moleculin Biotech, Inc., Moleculin Biotech, Inc., Nasdaq: MBRX, Annamycin Formulation, Walter Klemp, Phase 3 clinical stage, pharmaceutical company